Results 21 to 30 of about 6,071 (199)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

International Journal of Pediatrics, 2014
Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV ...
Nusrat Homaira, William Rawlinson, Thomas L. Snelling, Adam Jaffe   +3 more
doaj   +2 more sources

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation

Health Technology Assessment, 2008
Objectives: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with ...
D Wang, C Cummins, S Bayliss, J Sandercock, A Burls   +4 more
doaj   +2 more sources

Does Prophylaxis Against Respiratory Syncytial Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?

Journal of Behçet Uz Children's Hospital, 2021
Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun, İbrahim İlker Çetin, Hazım Alper Gürsu   +2 more
doaj   +1 more source

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation

Frontiers in Nutrition, 2020
Oral administration of engineered immunoglobulins has the potential to prevent enteric pathogen-induced diarrhea in infants. To prevent infection, these antibodies need to survive functionally intact in the proteolytic environment of the gastrointestinal
Baidya Nath P. Sah, Jiraporn Lueangsakulthai, Bum Jin Kim, Benjamin R. Hauser, Yeonhee Woo, Amy Olyaei, Molly Aloia, Ann O'Connor, Brian Scottoline, Manoj K. Pastey, David C. Dallas   +10 more
doaj   +1 more source

Linking pharmacy dispensing data to other administrative health datasets to measure the compliance and effectiveness of RSV immunoprophylaxis

International Journal of Population Data Science, 2018
Introduction Respiratory Syncytial Virus (RSV) causes considerable morbidity in children. RSV vaccines are in development, but the only current preventive measure is immunoprophylaxis with monoclonal antibody, palivizumab.
Hannah Moore, Tobias Strunk, Tasnim Abdalla, Tom Snelling, Peter Richmond, Anthony Keil, Nicholas de Klerk   +6 more
doaj   +1 more source

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BMC Pediatrics, 2020
Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV).
Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore   +7 more
doaj   +1 more source

Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge [PDF]

, 2018
BACKGROUND:Palivizumab provides passive immunity for respiratory syncytial virus (RSV), but poor adherence compromises protection. A hospital initiative promoted administration of first palivizumab doses at an outpatient clinic immediately after ...
Chen, Yanjun, Stockton, Winifred, Chilvers Murphy, Michelle, Lee, Tina, Allison Jun, Magedman, Grace, Tina Lee, Jun, Allison, Yanjun Chen, Grace Magedman, Michelle Chilvers Murphy, Winifred Stockton   +11 more
core   +1 more source

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study

Italian Journal of Pediatrics, 2023
Background In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study
Chiara Ratti, Anna della Greca, Deborah Bertoncelli, Monica Rubini, Bertrand Tchana   +4 more
doaj   +1 more source

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Emerging Infectious Diseases, 2012
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006–2010.
Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, Guy Boivin   +11 more
doaj   +1 more source

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source